Academic Journal
Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy
| العنوان: | Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy |
|---|---|
| المؤلفون: | Albert, F., Antoniewicz, A., Grantzow, T., Greis, A., Fingerle-Rowson, G., Ruf, P., Lindhofer, H., Kriegmair, M., Oberneder, R. |
| المصدر: | European Urology Open Science ; volume 45, page S234-S235 ; ISSN 2666-1683 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2022 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/s2666-1683(22)02578-2 |
| الاتاحة: | http://dx.doi.org/10.1016/s2666-1683(22)02578-2 https://api.elsevier.com/content/article/PII:S2666168322025782?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S2666168322025782?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: | edsbas.9E9AAF34 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/s2666-1683(22)02578-2 |
|---|